HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Read responses to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Braun, G. S Articles by Schmid, H. Search for Related Content PubMed PubMed Citation Articles by Braun, G. S Articles by Schmid, H.

Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects

¹ Division of Nephrology and Immunology, RWTH University, Aachen, Germany
² Medical Policlinic, Ludwig-Maximilians-University, Munich, Germany
³ Department of Dermatology, Ludwig-Maximilians-University, Munich, Germany
⁴ Renal Unit, Department of Medicine II, Klinikum Rechts der Isar, Technical University, Munich, Germany
⁵ Department of Pathology, Ludwig-Maximilians-University, Munich, Germany

Correspondence to:
Correspondence to:
Dr Holger Schmid
Medizinische Poliklinik, Ludwig-Maximilians-Universität München, Pettenkoferstr 8a, 80336 Munich, Germany; holger.schmid{at}lrz.uni-muenchen.de

Cryoglobulinaemia may cause cutaneous vasculitis and glomerulonephritis, potentially leading to end stage renal failure. An important proportion of cryoglobulinaemias are secondary to hepatitis C virus infection. Emerging antiviral treatment options offer a chance for causal therapy of these cases of cryoglobulinaemia. This review summarises the classification and clinical and therapeutic aspects of cryoglobulinaemic vasculitis and glomerulonephritis.

Abbreviations: ANCA, antineutrophil cytoplasmic antibody; HBV, hepatitis B virus; HCV, hepatitis C virus; MPGN, membranoproliferative glomerulonephritis

eLetters: